Michael D Stensland

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
    BMC Psychiatry 5:3. 2005
  2. ncbi Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care
    Michael D Stensland
    Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, United States
    J Affect Disord 101:187-93. 2007
  3. ncbi Diagnosis of unipolar depression following initial identification of bipolar disorder: a common and costly misdiagnosis
    Michael D Stensland
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychiatry 69:749-58. 2008
  4. ncbi Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
    Virginia S Haynes
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 12:222. 2012
  5. ncbi Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    Curr Med Res Opin 27:115-22. 2011
  6. ncbi Clinical comparability of schizophrenia patients at two public mental health systems
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Adm Policy Ment Health 30:231-45. 2003
  7. ncbi Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic
    Haya Ascher-Svanum
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Psychopharmacol 19:110-7. 2005
  8. ncbi Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder
    Baojin Zhu
    Eli Lilly and Company Lilly Research Laboratories, Indianapolis, IN, USA
    Curr Med Res Opin 23:2805-14. 2007
  9. ncbi An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia
    Sandra L Tunis
    Health Economics and Outcomes Research, IMS Health, Noblesville, IN, USA
    Curr Med Res Opin 23:97-104. 2007

Detail Information

Publications9

  1. ncbi Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
    Haya Ascher-Svanum
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
    BMC Psychiatry 5:3. 2005
    ..This study assessed the impact of acute treatment-emergent weight gain on clinical and functional outcomes of patients with schizophrenia by patient gender and antipsychotic treatment (olanzapine or haloperidol)...
  2. ncbi Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care
    Michael D Stensland
    Outcomes Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, United States
    J Affect Disord 101:187-93. 2007
    ..Bipolar disorder is a chronic and costly condition. This analysis examines health care costs associated with bipolar disorder in 2004 and contrasts them with those for depression, a better understood mental illness...
  3. ncbi Diagnosis of unipolar depression following initial identification of bipolar disorder: a common and costly misdiagnosis
    Michael D Stensland
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychiatry 69:749-58. 2008
    ..Bipolar disorder is challenging to diagnose in medical practice...
  4. ncbi Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
    Virginia S Haynes
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    BMC Psychiatry 12:222. 2012
    ..This post-hoc analysis of a 3-year study compared the costs of mental health services and functional outcomes between individuals with schizophrenia who met or did not meet cross-sectional symptom remission at study enrollment...
  5. ncbi Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia
    Haya Ascher-Svanum
    Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
    Curr Med Res Opin 27:115-22. 2011
    ..The objective of this study was to compare the cost-effectiveness of olanzapine to aripiprazole in the treatment of schizophrenia from the perspective of public payers in the United States...
  6. ncbi Clinical comparability of schizophrenia patients at two public mental health systems
    Haya Ascher-Svanum
    Eli Lilly and Company, Indianapolis, Indiana, USA
    Adm Policy Ment Health 30:231-45. 2003
    ....
  7. ncbi Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic
    Haya Ascher-Svanum
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Psychopharmacol 19:110-7. 2005
    ..88, p 0.05). Treatment-emergent weight gain appears to be an important marker of symptom reduction, and may not be exclusively attributable to pharmacological perturbations...
  8. ncbi Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder
    Baojin Zhu
    Eli Lilly and Company Lilly Research Laboratories, Indianapolis, IN, USA
    Curr Med Res Opin 23:2805-14. 2007
    ..Atypical antipsychotics are playing an increasing role in the treatment of bipolar disorder. The objective of this study was to assess the medication treatment patterns and costs associated with different atypical antipsychotics...
  9. ncbi An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia
    Sandra L Tunis
    Health Economics and Outcomes Research, IMS Health, Noblesville, IN, USA
    Curr Med Res Opin 23:97-104. 2007
    ..The objective of this study was to examine the ability of selected variables to predict antipsychotic persistence among patients receiving olanzapine or risperidone as initial treatment...